论文部分内容阅读
目的探讨尿脱氧吡啶啉（ＤＰＤ）排泄率对骨量减少的诊断意义。方法对４７例（男２７例，女２０例）糖尿病患者和４０例（男２０例，女２０例）正常健康人用ＥＬＩＳＡ双抗体夹心法测定尿脱氧吡啶啉排泄率。结果糖尿病患者ＤＰＤ排泄率（男５．８９±１．９３，女６．０１±２．２２ｎｍｏｌＬ－１ＤＰＤ／ｍｍｏｌＬ－１Ｃｒ）较正常对照组（男３．８７±１．５７，女３．６３±１．６８ｎｍｏｌＬ－１ＤＰＤ／ｍｍｏｌＬ－１Ｃｒ）明显增高（Ｐ＜０．０１）。而部分糖尿病患者骨密度降低尚达不到骨质疏松或骨量减少的诊断标准。结论ＤＰＤ排泄率是反映糖尿病骨量减少的敏感指标。
Objective To investigate the diagnostic value of urine deoxypyridinoline (DPD) excretion rate on bone mass loss. Methods 47 cases (27 males and 20 females) with diabetes mellitus and 40 normal (20 males and 20 females) healthy volunteers were tested for urinary deoxypyridine excretion rate by sandwich ELISA. Results DPD excretion rate (5.89 ± 1.93, 6.01 ± 2.22nmolL-1DPD / mmolL-1Cr) in diabetic patients was significantly higher than that in healthy controls (3.87 ± 1.57 vs 3.63 ± 3.66% 1.68nmolL-1DPD / mmolL-1Cr) was significantly higher (P <0.01). However, some patients with diabetes still do not achieve lower bone mineral density osteoporosis or osteopenia diagnostic criteria. Conclusions DPD excretion rate is a sensitive index reflecting the decrease of bone mass in diabetic patients.